Kaken Pharmaceutical Co., Ltd. (TYO:4521)
3,753.00
-42.00 (-1.11%)
May 14, 2025, 3:30 PM JST
Kaken Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 54,093 | 50,625 | 59,561 | 61,025 | 63,706 | Upgrade
|
Short-Term Investments | 15,992 | 14,699 | 14,699 | 13,599 | 13,599 | Upgrade
|
Cash & Short-Term Investments | 70,085 | 65,324 | 74,260 | 74,624 | 77,305 | Upgrade
|
Cash Growth | 7.29% | -12.03% | -0.49% | -3.47% | 5.43% | Upgrade
|
Receivables | 21,178 | 23,744 | 19,268 | 20,260 | 20,549 | Upgrade
|
Inventory | 19,020 | 17,167 | 15,563 | 14,980 | 15,197 | Upgrade
|
Other Current Assets | 1,094 | 739 | 812 | 749 | 611 | Upgrade
|
Total Current Assets | 111,377 | 106,974 | 109,903 | 110,613 | 113,662 | Upgrade
|
Property, Plant & Equipment | 27,629 | 25,355 | 25,498 | 25,734 | 25,020 | Upgrade
|
Long-Term Investments | 28,061 | 29,241 | 20,312 | 18,871 | 22,447 | Upgrade
|
Goodwill | 14,035 | - | - | - | - | Upgrade
|
Other Intangible Assets | 5,254 | 7,462 | 6,741 | 8,236 | 625 | Upgrade
|
Long-Term Deferred Tax Assets | 4,065 | 2,590 | 3,873 | 1,725 | 1,577 | Upgrade
|
Other Long-Term Assets | 1 | 1 | 1 | 2 | 1 | Upgrade
|
Total Assets | 190,422 | 171,623 | 166,328 | 165,181 | 163,332 | Upgrade
|
Accounts Payable | 8,322 | 7,099 | 6,219 | 5,939 | 8,569 | Upgrade
|
Accrued Expenses | 2,385 | 1,639 | 1,561 | 1,394 | 1,450 | Upgrade
|
Short-Term Debt | 3,850 | 3,850 | 3,850 | 3,850 | 3,850 | Upgrade
|
Current Income Taxes Payable | 13,596 | 4,222 | 7,828 | 5,979 | 5,294 | Upgrade
|
Other Current Liabilities | 2,201 | 2,214 | 1,380 | 1,887 | 2,113 | Upgrade
|
Total Current Liabilities | 30,354 | 19,024 | 20,838 | 19,049 | 21,276 | Upgrade
|
Long-Term Deferred Tax Liabilities | 1,514 | 1,947 | 1,771 | 2,229 | - | Upgrade
|
Other Long-Term Liabilities | 966 | 505 | 535 | 540 | 423 | Upgrade
|
Total Liabilities | 37,788 | 27,869 | 29,493 | 26,857 | 27,075 | Upgrade
|
Common Stock | 23,853 | 23,853 | 23,853 | 23,853 | 23,853 | Upgrade
|
Additional Paid-In Capital | 12,932 | 11,462 | 11,406 | 11,406 | 11,406 | Upgrade
|
Retained Earnings | 135,242 | 128,506 | 126,135 | 126,347 | 122,462 | Upgrade
|
Treasury Stock | -28,233 | -28,613 | -30,026 | -28,714 | -26,304 | Upgrade
|
Comprehensive Income & Other | 8,840 | 8,546 | 4,889 | 4,854 | 4,840 | Upgrade
|
Total Common Equity | 152,634 | 143,754 | 136,257 | 137,746 | 136,257 | Upgrade
|
Minority Interest | - | - | 578 | 578 | - | Upgrade
|
Shareholders' Equity | 152,634 | 143,754 | 136,835 | 138,324 | 136,257 | Upgrade
|
Total Liabilities & Equity | 190,422 | 171,623 | 166,328 | 165,181 | 163,332 | Upgrade
|
Total Debt | 3,850 | 3,850 | 3,850 | 3,850 | 3,850 | Upgrade
|
Net Cash (Debt) | 66,235 | 61,474 | 70,410 | 70,774 | 73,455 | Upgrade
|
Net Cash Growth | 7.75% | -12.69% | -0.51% | -3.65% | 5.73% | Upgrade
|
Net Cash Per Share | 1735.62 | 1629.01 | 1874.05 | 1863.55 | 1903.47 | Upgrade
|
Filing Date Shares Outstanding | 39.03 | 37.87 | 37.47 | 37.79 | 38.32 | Upgrade
|
Total Common Shares Outstanding | 39.03 | 37.87 | 37.47 | 37.82 | 38.32 | Upgrade
|
Working Capital | 81,023 | 87,950 | 89,065 | 91,564 | 92,386 | Upgrade
|
Book Value Per Share | 3910.48 | 3796.01 | 3636.14 | 3642.30 | 3555.92 | Upgrade
|
Tangible Book Value | 133,345 | 136,292 | 129,516 | 129,510 | 135,632 | Upgrade
|
Tangible Book Value Per Share | 3416.30 | 3598.97 | 3456.25 | 3424.53 | 3539.61 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.